Advisory

This advisory highlights the need for primary substance use prevention programs for young adults ages 18 to 25 with disabilities, provides guidance to prevention specialists on designing and tailoring these programs, and describes factors that may affect the delivery of prevention.

The article discusses the new FDA approval for the first nalmefene hydrochloride auto-injector for emergent treatment of a suspected opioid overdose.

This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This SAMHSA Advisory outlines the principles and components of low barrier care and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

The Pew Charitable Trusts

This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. It also focuses on the risks and harms of CBD and clarifies common misconceptions about CBD.

This Advisory is based on TIP 50, Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment. It provides strategies for identifying and addressing suicidal thoughts and behaviors among individuals with substance use disorders (SUDs).

This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders (SUDs) and TIP 32, Treatment of Adolescents with SUDs. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.